Kadmon Corporation LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$29.3M
Doctors Paid
59
Transactions
1,117
2021 Total
$9.6M
Payment Breakdown by Category
Research$24.0M (81.7%)
Consulting$408,631 (1.4%)
Travel$54,626 (0.2%)
Food & Beverage$17,878 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $24.0M | 821 | 81.7% |
| Current or prospective ownership or investment interest | $4.2M | 2 | 14.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $626,859 | 60 | 2.1% |
| Consulting Fee | $408,631 | 45 | 1.4% |
| Travel and Lodging | $54,626 | 58 | 0.2% |
| Grant | $22,000 | 3 | 0.1% |
| Food and Beverage | $17,878 | 126 | 0.1% |
| Charitable Contribution | $5,000 | 1 | 0.0% |
| Education | $300.00 | 1 | 0.0% |
Payments by Type
Research
$24.0M
821 transactions
General
$5.4M
296 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Double blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects with Autosomal Dominant Polycystic Kidney Disease | $4.7M | 0 | 175 |
| A Randomized Phase 2 Open Label Multicenter Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects with Idiopathic Pulmonary Fibrosis IPF | $3.0M | 0 | 63 |
| A Randomized Phase 2 Open Label Multicenter Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | $2.1M | 0 | 39 |
| A Phase 1b 2a Safety Pharmacokinetic and Dose Escalation Study of KD019 in Subjects with Autosomal Dominant Polycystic Kidney Disease | $1.3M | 0 | 43 |
| A Phase 2 Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment with a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases | $1.2M | 0 | 32 |
| A Phase 2 Randomized Double Blind Placebo Controlled Dose Finding Study to Evaluate the Safety Tolerability and Efficiacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy | $1.2M | 0 | 56 |
| A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease | $1.1M | 0 | 27 |
| A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma | $971,738 | 0 | 38 |
| A Phase 2 Randomized Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease cGVHD After at Least 2 Prior Lines of Systemic Therapy | $962,773 | 0 | 48 |
| A Phase I Randomized Doubleblind Placebo and Positivecontrolled Crossover Study to Investigate the Effects of Belumosudil on QTc Interval in Healthy Subjects | $902,763 | 0 | 1 |
| A Phase 1 First in Human Randomized PlaceboControlled DoubleBlind Single and Multiple Ascending Dose Study of KD045 | $842,892 | 0 | 1 |
| A Phase 2a DoseEscalation OpenLabel Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease | $700,022 | 0 | 12 |
| A Phase 1 OpenLabel MultipleAscending Dose Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors | $641,354 | 0 | 6 |
| A Phase 2a Dose Escalation Open Label Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects with Chronic Graft Versus Host Disease | $512,505 | 0 | 14 |
| A Single-dose, Open-label, Pharmacokinetic Study of KD025 in Subjects With Normal Hepatic Function & Subjects With Varying Degrees of Hepatic Impairment | $497,016 | 0 | 3 |
| A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) | $475,606 | 0 | 11 |
| A Phase 2 Randomized Placebo controlled Double blind Open label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis | $397,480 | 0 | 38 |
| A Phase 2, Randomized, Placebo controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis | $365,071 | 0 | 39 |
| A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After at Least 2 Prior Lines of Systemic Therapy | $317,652 | 0 | 28 |
| A Phase 2 Multicenter Study of Tesevatinib in Subjects with NonSmall Cell Lung Cancer EGFR Activating Mutation Prior Treatment with a Tyrosine Kinase Inhibitor and Brain Metastases or Leptomeningeal Metastases | $209,190 | 0 | 16 |
| A Phase 1, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. | $201,056 | 0 | 2 |
| A Phase 2 Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma | $192,612 | 0 | 14 |
| A Phase 2a Dose Escalation Open Label Study to Evaluate the Safety Tolerability and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease | $187,763 | 0 | 14 |
| A Phase 2 Openlabel Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects with Diffuse Cutaneous Systemic Sclerosis | $166,774 | 0 | 7 |
| A Phase 2 Randomized Double Blind Placebo Controlled Dose Finding Study to Evaluate the Safety Tolerability and Efficiacy of KD025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or | $146,681 | 0 | 33 |
| A Phase 2 Randomized Placebo controlled Doubleblind Openlabel Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis | $132,137 | 0 | 20 |
| Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment with Tesevatinib on Study KD019-101 in Subjects with Autosomal Dominant Polycystic Kidney Disease | $85,535 | 0 | 8 |
| A Phase 1b 2a Study of the combination of KD019 and Trastuzumab in Subjects with HER2 Positive Metastic Breast Cancer | $73,324 | 0 | 6 |
| An Open Label, Two-Period, Crossover Bioequivalence Study of Trientine Hydrochloride (KD034) Capsules to Trientine Hydrochloride (SYPRINE) Capsules in Healthy Volunteers | $67,754 | 0 | 1 |
| A Phase 1, Randomized, Double-blind, Placebo-and Positive-controlled, Parallel Group Study to Investigate the Effects of Belumosudil on QTc Interval in Healthy Subjects | $65,066 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Dermatology | $2.4M | 1 | $2.4M |
| Diagnostic Radiology | $174,339 | 2 | $87,170 |
| Pediatrics | $74,911 | 4 | $18,728 |
| Family Medicine | $73,241 | 1 | $73,241 |
| Internal Medicine | $51,284 | 10 | $5,128 |
| Anatomic Pathology | $27,250 | 1 | $27,250 |
| Hematology & Oncology | $23,176 | 10 | $2,318 |
| Nephrology | $9,855 | 2 | $4,928 |
| Medical Oncology | $6,015 | 3 | $2,005 |
| Neurology | $4,786 | 3 | $1,595 |
| Critical Care Medicine | $2,957 | 2 | $1,478 |
| Cardiovascular Disease | $2,409 | 2 | $1,205 |
| Pediatric Nephrology | $2,000 | 1 | $2,000 |
| Hematology | $1,274 | 1 | $1,274 |
| Gastroenterology | $620.20 | 4 | $155.05 |
| Pediatric Gastroenterology | $183.33 | 1 | $183.33 |
| Pediatric Transplant Hepatology | $183.33 | 1 | $183.33 |
| General Practice | $138.22 | 2 | $69.11 |
| Pulmonary Disease | $135.42 | 1 | $135.42 |
| Medical Toxicology | $132.48 | 1 | $132.48 |
| Ophthalmology | $123.84 | 1 | $123.84 |
| Plastic Surgery | $104.59 | 1 | $104.59 |
| Hepatology | $70.21 | 1 | $70.21 |
| Physician Nutrition Specialist | $53.36 | 1 | $53.36 |
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Fernando Martinez, Md, MD | Critical Care Medicine | Worcester, MA | $98.08 | $0 |
| Michael Schilsky, Md, MD | Internal Medicine | New Haven, CT | $95.21 | $0 |
| Robert Greenbaum, Md, MD | Diagnostic Radiology | Jamaica, NY | $89.07 | $0 |
| Dr. Mered Parnes, M.d, M.D | Pediatrics | Houston, TX | $70.21 | $0 |
| Norman Sussman, Md, MD | Hepatology | Houston, TX | $70.21 | $0 |
| Frederick Askari, Md, Phd, MD, PHD | Gastroenterology | Ann Arbor, MI | $70.21 | $0 |
| Jonathan Schwartz, Md, MD | Hematology & Oncology | New York, NY | $55.91 | $0 |
| Laurence Blumberg, M.d, M.D | Physician Nutrition Specialist | New York, NY | $53.36 | $0 |
| Dr. Jacqueline Mays, D.d.s, Ph.d, D.D.S, PH.D | General Practice | Rockville, MD | $22.77 | $0 |
Ad
Payment Categories
- Food & Beverage $17,878
- Consulting $408,631
- Travel & Lodging $54,626
- Research $24.0M
About Kadmon Corporation LLC
Kadmon Corporation LLC has made $29.3M in payments to 59 healthcare providers, recorded across 1,117 transactions in the CMS Open Payments database. In 2021, the company paid $9.6M.
Payments were distributed across 24 medical specialties. The top specialty by payment amount is Dermatology ($2.4M to 1 doctors).
Payment categories include: Food & Beverage ($17,878), Consulting ($408,631), Research ($24.0M), Travel & Lodging ($54,626).